Table 4. Contemporary Chemotherapy Regimens for Children and Adolescents with Hodgkin Lymphoma
| Name | Drugs | Dosage | Route | Days |
| IV = intravenous; PO = oral. | ||||
| COPP [40] | Cyclophosphamide | 600 mg/m2 | IV | 1, 8 |
| Vincristine (Oncovin) | 1.4 mg/m2 | IV | 1, 8 | |
| Procarbazine | 100 mg/m2 | PO | 1–15 | |
| Prednisone | 40 mg/m2 | PO | 1–15 | |
| COPDAC [40] | Dacarbazine substituted for procarbazine in COPP | 250 mg/m2 | IV | 1–3 |
| OPPA [40] | Vincristine (Oncovin) | 1.5 mg/m2 | IV | 1, 8, 15 |
| Procarbazine | 100 mg/m2 | PO | 1–15 | |
| Prednisone | 60 mg/m2 | PO | 1–15 | |
| Doxorubicin (Adriamycin) | 40 mg/m2 | IV | 1, 15 | |
| OEPA [40] | Vincristine (Oncovin) | 1.5 mg/m2 | IV | 1, 8, 15 |
| Etoposide | 125 mg/m2 | IV | 3–6 | |
| Prednisone | 60 mg/m2 | PO | 1–15 | |
| Doxorubicin (Adriamycin) | 40 mg/m2 | IV | 1, 15 | |
| ABVD [7] | Doxorubicin (Adriamycin) | 25 mg/m2 | IV | 1, 15 |
| Bleomycin | 10 U/m2 | IV | 1, 15 | |
| Vinblastine | 6 mg/m2 | IV | 1, 15 | |
| Dacarbazine | 375 mg/m2 | IV | 1, 15 | |
| COPP/ABV [14] | Cyclophosphamide | 600 mg/m2 | IV | 0 |
| Vincristine (Oncovin) | 1.4 mg/m2 | IV | 0 | |
| Procarbazine | 100 mg/m2 | PO | 0–6 | |
| Prednisone | 40 mg/m2 | PO | 0–13 | |
| Doxorubicin (Adriamycin) | 35 mg/m2 | IV | 7 | |
| Bleomycin | 10 U/m2 | IV | 7 | |
| Vinblastine | 6 mg/m2 | IV | 7 | |
| VAMP [41] | Vinblastine | 6 mg/m2 | IV | 1, 15 |
| Doxorubicin (Adriamycin) | 25 mg/m2 | IV | 1, 15 | |
| Methotrexate | 20 mg/m2 | IV | 1, 15 | |
| Prednisone | 40 mg/m2 | PO | 1–14 | |
| DBVE [42,43] | Doxorubicin | 25 mg/m2 | IV | 1, 15 |
| Bleomycin | 10 U/m2 | IV | 1, 15 | |
| Vincristine (Oncovin) | 1.5 mg/m2 | IV | 1, 15 | |
| Etoposide | 100 mg/m2 | IV | 1–5 | |
| ABVE-PC [34] | Doxorubicin (Adriamycin) | 30 mg/m2 | IV | 0, 1 |
| Bleomycin | 10 U/m2 | IV | 0, 7 | |
| Vincristine (Oncovin) | 1.4 mg/m2 | IV | 0, 7 | |
| Etoposide | 75 mg/m2 | IV | 0–4 | |
| Prednisone | 40 mg/m2 | PO | 0–9 | |
| Cyclophosphamide | 800 mg/m2 | IV | 0 | |
| BEACOPP [44] | Bleomycin | 10 U/m2 | IV | 7 |
| Etoposide | 200 mg/m2 | IV | 0–2 | |
| Doxorubicin (Adriamycin) | 35 mg/m2 | IV | 0 | |
| Cyclophosphamide | 1200 mg/m2 | IV | 1, 8 | |
| Vincristine (Oncovin) | 2 mg/m2 | IV | 7 | |
| Prednisone | 40 mg/m2 | PO | 0–13 | |
| Procarbazine | 100 mg/m2 | PO | 0–6 | |
| CVP [45] | Cyclophosphamide | 500 mg/m2 | IV | 1 |
| Vinblastine | 6 mg/m2 | IV | 1, 8 | |
| Prednisolone | 40 mg/m2 | PO | 1–8 | |
References
- Bonadonna G, Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 9 (1): 21-35, 1982. [PUBMED Abstract]
- Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (18): 3765-71, 2002. [PUBMED Abstract]
- Schwartz CL, Constine LS, Villaluna D, et al.: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114 (10): 2051-9, 2009. [PUBMED Abstract]
- Mauz-Körholz C, Hasenclever D, Dörffel W, et al.: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28 (23): 3680-6, 2010. [PUBMED Abstract]
- Donaldson SS, Link MP, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25 (3): 332-7, 2007. [PUBMED Abstract]
- Tebbi CK, Mendenhall N, London WB, et al.: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 46 (2): 198-202, 2006. [PUBMED Abstract]
- Tebbi CK, Mendenhall NP, London WB, et al.: Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 59 (7): 1259-65, 2012. [PUBMED Abstract]
- Kelly KM, Sposto R, Hutchinson R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117 (9): 2596-603, 2011. [PUBMED Abstract]
- Shankar A, Hall GW, Gorde-Grosjean S, et al.: Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer 48 (11): 1700-6, 2012. [PUBMED Abstract]
